Xarelto sales fall 30% due to generics and price cuts
By | translator Alice Kang
22.10.25 12:09:58
가나다라
0
No big change seen in the prescription volume...expected to make lower KRW 50 billion range this year
Sales of Xarelto generics KRW 2.4 billion... Chong Kun Dang runs ahead making KRW 0.8 billion
The quarterly prescription of new oral anticoagulants (NOAC) containing rivaroxaban, which had reached KRW 15 billion, has shrunk to KRW 13 billion. This decrease is interpreted to be reflected by the price cut of Bayer’s original ‘Xarelto.’ Its generics that entered the market 1 year ago have been starting to slowly increase their share in the market, making KRW 2.4 billion in total.
◆Xarelto takes a direct blow from drug price cuts...Quarterly sales record KRW 11.3 billion
According to the market research institution UBIST on the 25th, the domestic outpatient prescriptions of rivaroxaban recorded KRW 13.7 billion in Q3 this year, falling fell 16% compared to the KRW 16.4 billion
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)